Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder
- 1 September 2021
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 54, 103143
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Disease exacerbation after rituximab induction in neuromyelitis opticaNeurology Neuroimmunology & Neuroinflammation, 2015
- A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum DisorderJAMA Neurology, 2013
- Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis opticaNeurology, 2013
- Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 TherapyJAMA Neurology, 2013
- Lack of response to rituximab therapy in patients with neuromyelitis optica: True non-responders or insufficient treatment?Journal of the Neurological Sciences, 2012
- Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disordersJournal of Neuroinflammation, 2011
- Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levelsJournal of Clinical Neuroscience, 2011
- Variable responses to rituximab treatment in neuromyelitis optica (Devic’s disease)Neurological Sciences, 2007
- B-cell targeting in rheumatoid arthritis and other autoimmune diseasesNature Reviews Immunology, 2006
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004